Reimbursement
Population health outfit Caradigm has announced it will be forming what it calls a Care Transformation Team that it claims will help improve the outcomes of population health initiatives for the providers it serves.
In 2016, health insurance co-ops have gained needed enrollment but half of those set up under the Affordable Care Act three years ago have failed, costing taxpayers over $1 billion, according to a Senate subcommittee which has investigated what went wrong.
Isaac Kojo Anakwah Thompson, a Florida doctor who falsely diagnosed hundreds of patients as having a rare spine condition, has pleaded guilty to healthcare fraud and faces spending a decade in prison.
The following database lists the individual skilled nursing facilities, their total number of stays, average length of stays, total charges, Medicare payments and Medicare allowances.
Physician and pharmaceutical groups have come out swinging against the Centers for Medicare and Medicaid Services' proposal to reduce the reimbursement price for Medicare Part B prescription drugs.
The state of Vermont announced it has reduced the amount it pays the University of Vermont Medical Center, as well as six other hospitals, to treat Medicaid patients.
In a 'major milestone' for the Affordable Care Act, 30 percent of Medicare payments are now made through alternative payment models.
LAS VEGAS – Officials from the Centers for Medicare and Medicaid Services on Wednesday said physicians should expect meaningful use of electronic health records to still be required under coming changes to how CMS pays them under MACRA.
LAS VEGAS -- When Inova Health saw that Affordable Care Act initiatives for value-based care would cut 7 percent, or $220 million, out of the $3 billion health system's successful fee-for-service revenues, the northern Virginia provider knew it needed to change, said President and COO Mark Stauder.
MIT Sloan Professor Andrew Lo, Dana-Farber Cancer Institute's David Weinstock, and MIT post-doctoral fellow Vahid Montazerhodjat have identified this as a time when breakthrough therapies for certain types of cancers, hepatitis C, and rare diseases exist but remain out of reach for many patients, due primarily to the prohibitive cost.